YEAR-END REPORT 2008
TRIPEP AB (PUBL)

- Research and development costs amounted to SEK 17.1 (21.3) m
- The loss after tax was SEK -24.9 (-32.7) m
- Earnings per share were SEK -2.29 (-5.59)
- Net sales SEK 3,8 (-) m
- The company carried out a private placement during the fourth quarter 2008 which raised SEK 5 m, and a rights issue which raised approx. SEK 4.9 m before transaction costs
- After an interim analysis of available study data in November the last three patients are enrolled for high-dose treatment in the ChronVac-C® study
- Tripep secured a US patent which is strengthening our position regarding ChronVac-C®
- Patent application filed for a new antibiotic-free formulation of ChronSeal® in collaboration with Kringle Pharma, Inc.
- Tripep has obtained an approval from the Norwegian Medical Products Agency to start the phase II study with ChronSeal® and the study started in January 2009
- Tripep secures financing in ChronSeal® through a new agreement with Kringle Pharma, Inc.

Events after the end of the reporting period

- Tripep has obtained an approval from the Swedish Medical Products Agency to start the phase II study with ChronSeal® and the study expects to start in Sweden in February 2009
- Through Tripep's partner Kringle Pharma a letter of intent has been signed with the Japanese specialty pharma company Maruho regarding ChronSeal®

Tripep develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologies. The company's main focuses are: the wound healing therapy ChronSeal®, the therapeutic vaccine against Hepatitis C named ChronVac-C® plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please visit: www.tripep.se

In the event of any discrepancy between the Swedish an English Interim Reports, the Swedish version will take precedence.

ChronVac-C®–Therapeutic Vaccine against Hepatitis C

Tripep have during 2008 reported on the first nine patients that had completed therapy in ongoing open phase I/II trial. In the low dose group a short lived T-cell activation was observed in 2 out of 3 patients which did not reduce the viral levels in the blood. In the high- and intermediate dose group, in 2 out of 3 patients respectively, a significant lowering if viral levels, often coinciding with a T-cell activation was observed. This is a proof-of-concept that ChronVac-C® therapy has an antiviral effect. No unexpected or serious side effects have been noted. These results were presented at the annual American liver meeting (AASLD) in San Francisco in November and was officially noted as one of the most interesting presentations. Following an interim analysis in November the enrolment of the three last patients for treatment with the highest dose of ChronVac-C® has started. These patients will be treated with the highest dose of ChronVac-C®.

This study involves previously untreated patients with chronic hepatitis C virus infection with low levels of genotype 1 virus. Each patient will receive four vaccinations at one-month intervals, after which they will be monitored for six months. The main purpose of the study is to demonstrate the safety of the treatment. The study will also test if the treatment boosts the host immune response to hepatitis C, as well as studying the effect on virus replication. This is the first study in the world where a DNA vaccine is being used to treat patients with chronic Hepatitis C virus infection. It is also the first time a DNA vaccine against an infectious agent is being administered by in vivo electroporation in humans.

ChronVac-B – Therapeutic Vaccine against Hepatitis B

Tripep signed a letter of intent with Inovio Inc. of San Diego regarding the joint development of ChronVac-B, a therapeutic vaccine against chronic hepatitis B viral infection. During 2008 the work with selecting a candidate drug progressed. The new partnership between Tripep and Inovio is based on the combination of Tripep's ChronVac-B technology, which is administered using Inovio's *in vivo* electroporation technology.

An estimated 400 million people suffer from chronic infection, and these are exposed to an increased risk of serious liver damage and cancer. Currently approved drugs have problems with side effects or the development of antiviral resistance, implying a considerable need for improving treatment of patients with chronic hepatitis B viral infection. A therapeutic vaccine is intended to improve the infected individual's chances of gaining control of the infection through the specific activation of the immune defence. Currently, there are only preventative vaccines against hepatitis B on the market.

ChronSeal® – Treating Chronic Wounds

ChronSeal®, the patent applied therapy for the treatment of chronic wounds in the skin, based on hepatocyte growth factor (HGF) protected in an unique patent applied antibiotic free formulation, has been approved for phase II testing by the Norwegian Medicines Agency in October and by the Swedish Medical Products Agency on the 23rd of January 2009.

In the study two different dose levels will be evaluated versus placebo. 75 patients will be enrolled from four centers in Sweden and four in Norway. The patients will be treated for one week with ChronSeal® as an add on to regular dressing and will thereafter be followed for another 11 weeks to monitor if a sustained healing of the wounds has been achieved. Since HGF's mechanism is to start the healing process, longer treatment periods are not expected to give additional healing effects. Only those patients will be included in the study whose wounds do not heal by more than 50% during a 14 day's run in period with standard dressing. The main purpose of the study is to demonstrate the safety of ChronSeal® but also to evaluate the clinical efficacy. The study started in Norway in January 2009.

Other Research Projects

The international journal New Scientist, popular science publisher and the well renowned American scientific journal "Proceedings of the National Academy of Sciences" (PNAS) in the end of August both commented on a scientific work from Tripep published in PNAS . The research article was written in collaboration with the Karolinska Institutet about Tripep's entirely new and patented immune therapy for attacking HIV. In the article, the researchers describe the further development of Tripep's RAS-technology and how "molecular adapters" make otherwise superfluous natural antibodies into attackers of HIV and HIV-infected cells. This technique opens up for commercial development of a totally new type of medication against HIV and for other infections as well as other instances when antibodies can be of importance, such as for the treatment of cancer.

Collaboration Agreements

Tripep has renegotiated the agreement with its Japanese partner Kringle Pharma Inc. regarding the wound healing project ChronSeal®. According to the new agreement Kringle Pharma takes on the economic responsibility, including Tripep's internal costs, for the upcoming clinical study. Tripep reduces its share in the project but retains a right to buy back an increased share in the project. This means that currently Tripep carries no risk in the project. Tripep received an upfront payment of ca 3.8 MSEK. The value of the agreement corresponds to slightly more SEK 19 m in saved costs for the ChronSeal project which is now taken over by Kringle Pharma, Inc. In return Tripep's share in the project was lowered from present 60% to 10%, but with a right to buy back into the project with up to 50% before the 31st of March 2009 and up to 40% until the 30th of June 2010. Should Tripep chose not to buy back sharing in the project Tripep will still retain 10% of all revenue from the project.

In addition, Tripep has a collaboration agreement with US Corporation Inovio regarding the joint development of Tripep's therapeutic vaccine ChronVac-C®. This collaboration has given the company access to world-leading technology for administering DNA vaccines.

Moreover, the company signed a letter of intent with Inovio Inc. regarding the joint development of ChronVac-B.

Patents

Tripep's strategy is to secure patent protection in the regions significant to the company, i.e. North America, Europe and Asia. The patent portfolio consists of 58 approved patents and 36 patents pending.

Employees

The company had 5 (7) employees at the end of the period.

Profit/Loss

The company has sold part of the ChronSeal project for a purchase price of SEK 3.8 m, for more information see "Collaboration Agreements" above. The SEK 0.7 m under other operating income relates to Management fees SEK 0.6 m related to the ChronSeal® project and SEK 0.1 m EU subsidies received.

Operating costs were SEK 5.7 (11.0) m for the fourth quarter 2008 and SEK 29.4 (33.4) m for the full year 2008.

The loss after financial items was SEK -1.4 (-11.0) m for the fourth quarter 2008 and SEK -24.9 (-32.7) m for the full year 2008.

Research and development costs were SEK 2.5 (8.0) m for the fourth quarter 2008, of which external researchers and subcontractors were SEK 2.4 (7.6) m. Research and development costs were SEK 17.1 (21.3) m for the full year 2008, of which external researchers and subcontractors were SEK 16.2 (20.2) m.

Investments

Net investments in equipment amounted to SEK 0.0 (0.0) m during the fourth quarter 2008 and SEK 0.1 (0.2) m during the full year 2008.

Tripep has acquired a subsidiary. At the end of the reporting period the cash and bank balances in the subsidiary amounted to SEK 0.1 m.

Furthermore the company has, together with Kringle Pharma, Inc., formed a company named Kringle Pharma Europe AB, where Tripep holds 25 % of the shares. Fore more information see "Collaboration Agreement".

Financial Position

The company's liquid assets amounted to SEK 3.3 (5.3) m as of 31 December 2008. The remaining SEK 1.8 m in the recently consummated rights issue has been paid in January 2009. The proceeds from the rights issue mean that the company will have sufficient working capital to conduct operations to the second quarter 2009. The Board continously explores financing opportunities of which one option may be through new issues.

As of 31 December 2008, shareholders' equity was SEK -1.1 (-1.6) m. As of 31 December 2008 the Board of Directors has prepared a balance sheet for liquidation purposes showing that the equity is intact. The balance sheet for liquidation purposes has been reviewed by the company auditor.

As of 31 December 2008 the company share capital amounts to SEK 1,995,041.20, including SEK 616,418.80 paid-up but not yet registered at the Swedish Companies Registration Office (registration took place 15 January 2009).

As of 31 December 2008, after the reverse stock split, the number of shares was 19,950,412, including 6,164,188 shares, paid-up but not yet registered at the Swedish Companies Registration Office. Each share has a nominal value of SEK 0.10.

Long-term liabilities were SEK 1.9 (3.0) m as of 31 December 2008, a commitment over five years that Tripep undertook coincident with the acquisition of the ChronSeal® wound healing project.

Current liabilities amounted to SEK 6.3 (6.5) m as of 31 December 2008.

Rights issue

An EGM of Tripep AB on 19 December 2007 resolved on the new issue of 48,260,870 units (one unit = one new share and one new option) with preferential rights for existing shareholders, which upon full subscription, would raise SEK 24 m for the company before issue costs. In total 32,418,905 Units were subscribed for resulting in a capital injection of app. SEK 16.2 m before transaction costs of app. SEK 1.3 m.

During the third quarter 2008, Tripep has, based on the authorization by the AGM of 9 April 2008, carried out another rights issue with a maximum of 8,067,978 Units, which fully subscribed would have given Tripep approx. SEK 16.1 m before transaction costs. 1,718,246 Units were subscribed for, resulting in a capital injection of app SEK 3.4 m before transaction costs.

During the fourth quarter 2008, Tripep has carried out a private placement of 4,000,000 shares at a subscription price of SEK 1.25. Tripep raises SEK 5 m through the placement.

Furthermore, Tripep has carried out a rights issue during the fourth quarter 2008, raising the company SEK 3.1 m before transaction costs as of December 31 2008. The remaining SEK 1.8 m has been paid in January 2009.

Warrants

There are 32,418,905 TO2 warrants. After recalculation, due to the reverse stock split and the rights issue in November 2008, twenty TO2 confers the right to subscribe for 1.2 shares with an exercise price of SEK 8.35 per share during the period 1 April 2008 to 30 September 2009. TO2 warrants are traded on First North. Upon full exercise of TO2 the company would raise app. SEK 16.2 m and another 1,945,134 shares will be issued.

TO3 has expired on 1 December 2008, raising the company SEK 5,732.

Stock Option Plan

The company has one staff stock option plan involving 600,000 staff stock options in three series (B-D) with expiry on 30 June 2009, 2010 and 2011. Series A (150,000) has expired without any options being exercised. As a consequence of the reverse stock split 1:10 and the rights issue in November 2008 the exercise price for warrants B-D have been recalculated: exercise price for series B was SEK 2.03 and has been recalculated to SEK 16.94, exercise price for series C was SEK 2.29 and has been recalculated to SEK 19.11, exercise price for series D was SEK 2.54 and has been recalculated to SEK 21.19. After the reverse stock split 10 options (series B-D) confers the right to subscribe for 1.37 shares.

Risks and Uncertainty Factors

The financial risks are primarily associated with Tripep's business risk and possibilities to finance development.

For ChronVac-C®, the biggest risk is assessed to be that the main product ChronVac-C®, at the dosages administered, will not activate a human immune response of sufficient strength.

ChronSeal® is subject to the risk that the positive clinical effects of ChronSeal® cannot be repeated in future clinical trials.

In addition, there can be no guarantee that the clinical trials conducted by Tripep are able to demonstrate with sufficient clarity that potential products are sufficiently safe and effective. In such case, approval may not be forthcoming for these products, which would adversely affect Tripep's operations, financial position and earnings.

Another risk Tripep is exposed to lies in its competitive market, with the risk of new and better pharmaceuticals from competing companies.

For a more in-depth discussion of the company's exposure to risk, please refer to the Risk Factors section (pages 22-23) and note 17 of Tripep's Annual Report 2007, and the Risk Factors section in Tripep's Prospectus, August 2008 (only available in Swedish).

Authorisation to decide on new issues of shares, convertibles and warrants

The AGM authorised the Board to decide on the new issue of shares, convertible debentures and/or warrants against cash payment and/or to decide on non-cash or set-off issues or subject to other terms, and thus to waive shareholders' preferential rights, on one or more occasions in the period until the next AGM.

Events after the End of the Reporting Period

Tripep has obtained an approval from the Swedish Medical Products Agency to start the phase II study with ChronSeal® and the study expects to start in Sweden in February 2009.

Through Tripep's partner Kringle Pharma a letter of intent has been signed with the Japanese specialty pharma company Maruho regarding ChronSeal®, Tripep's and Kringle Pharma's co-owned product for the treatment of chronic leg wounds. The letter of intent gives Maruho a first right to evaluate the results from the ongoing phase I/II study and to negotiate the marketing rights for the Japanese market.

Annual General Meeting (AGM)

Tripep's AGM 2009 will be held on 1 April at 6 p.m. in the Sydney Conference Facility, World Trade Center Stockholm, Klarabergsviadukten 70 (alternative entrance Kungsbron 1), Stockholm, Sweden.

The Annual Report for 2008 will be available from Tripep's Website www.tripep.se. If requested it will be sent to individual shareholders. The Swedish version will be available by no later than two weeks before the AGM 2009.

Accounting Policies

This Year-end Report has been compiled in accordance with the Swedish Accounting Standards Board's general recommendations for voluntary interim reporting, BFNAR 2007:1. The accounting policies applied are consistent with those applied when preparing the 2007 Annual Report.

Forthcoming Financial Reports

Annual Report	March 2009
Annual General Meeting	1 April 2009
First-quarter Interim Report	24 April 2009
Second-quarter Interim Report	26 August 2009
Third-quarter Interim Report	23 October 2009
Year-end Report 2009	29 January 2010

The Board of Directors and the Chief Executive Officer hereby declare that the Interim Report gives a true and fair view of the company's operations, financial position and results, and that it accurately reviews the material risks and uncertainties facing the company.

Huddinge, Sweden, 30 January 2009

Thomas Lynch
Chairman

Anders Vahlne
Board member

Matti Sällberg
Board member

Jan Nilsson
CEO

This Year End Report has not been subject to review by the company's auditors

FOR MORE INFORMATION, PLEASE CONTACT:

Jan Nilsson, Chief Executive Officer
Tel +46(0)8 449 8482, mobile +46 (0)70 466 3163
e-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research
Tel +46 (0)8 585 81313, mobile +46 (0)70 928 0528
e-mail: anders.vahlne@ki.se

INCOME STATEMENT

SEK m	3 mth. Oct-Dec 2008	3 mth. Oct-Dec 2007	12 mth. Jan-Dec 2008	12 mth. Jan-Dec 2007
Net sales	3.8	-	3.8	-
Other operating income	0.6	0.0	0.7	0.0
Total operating income	**4.4**	**0.0**	**4.5**	**0.0**
Operating costs				
Other external costs [1)]	-3.7	-8.9	-20.9	-25.2
Payroll costs	-2.0	-2.0	-8.3	-8.0
Depreciation of tangible fixed assets	-0.0	-0.1	-0.2	-0.2
Total operating costs	**-5.7**	**-11.0**	**-29.4**	**-33.4**
Operating profit/loss	**-1.3**	**-11.0**	**-24.9**	**-33.4**
Profit/loss from financial investments				
Interest income and similar profit/loss items	0.0	0.0	0.2	0.7
Interest costs and similar profit/loss items	-0.1	-	-0.2	-
Total profit/loss from financial investments	**-0.1**	**0.0**	**0.0**	**0.7**
Profit/loss after financial items	**-1.4**	**-11.0**	**-24.9**	**-32.7**
Tax on net profit/loss	-	-	-	-
Net profit/loss for the period	**-1.4**	**-11.0**	**-24.9**	**-32.7**

1) R&D costs specified under key figures on p. 6

EARNINGS PER SHARE

SEK	3 mth. Oct-Dec 2008	3 mth. Oct-Dec 2007	12 mth. Jan-Dec 2008	12 mth. Jan-Dec 2007
Earnings per share	-0.09	-1.88	-2.29	-5.59
Earnings per share after dilution	-0.09	-1.88	-2.29	-5.59
Outstanding average number of shares	16,121,930	5,855,054	10,896,088	5,848,568

Earnings per share: net profit/loss divided by the average number of shares. Earnings after dilution: net profit/loss divided by the average number of shares after dilution. No outstanding options give rise to any dilution effect when calculating earnings per share. Conversion has been affected for the bonus issue element of consummated rights issue.

Conversion has been affected for the reverse stock split 1:10 carried out in June 2008.

NUMBER OF OUTSTANDING SHARES

	3 mth. Oct-Dec 2008	3 mth. Oct-Dec 2007	12 mth. Jan-Dec 2008	12 mth. Jan-Dec 2007
No. of outstanding shares, opening balance	9,786,224	4,826,087	4,826,087	4,813,499
New issue, TO1	-	-	-	12,588
Rights issue	-	-	4,960,137	-
Private placement	4,000,000	-	4,000,000	-
Rights issue[1)]	6,161,322	-	6,161,322	-
New issue, TO3[1)]	2,866	-	2,866	-
Outstanding number of shares, closing balance	19,950,412	4,826,087	19,950,412	4,826,087

A statement of changes in equity is presented on page 19 in Tripep's Annual Report 2007, and in Tripep's Prospectus August 2008, page 39

Conversion has been affected for the reverse stock split 1:10 carried out in June 2008.

1) 6,164,188 shares, paid-up, registered at the Swedish Companies Registration Office on 15 January 2009.

WARRANTS

	Number	Of which the company owns	Of which the staff	Exercise Price, SEK	Subscription Period
Series B	200,000	50,000	150,000	16.94	1-30 June 2009
Series C	250,000	62,500	187,500	19.11	1-30 June 2010
Series D	350,000	87,500	262,500	21.19	1-30 June 2011
TO2	32,418,905		Rights issue	8.35	1 Apr 2008-30 Sep 2009

Series A has expired on 30 June 2008 without any options being exercised.
Series B-D - ten options confers the right to subscribe for 1.37 shares. As a consequence of the rights issue and the reverse stock split the terms have been recalculated. At the end of the period, there were 560,000 staff stock options, because 40,000 had expired due to terminated employment, and 150,000 serie A has expired on 30 June 2008 without being exercised.
TO2 - twenty options confer the right to subscribe for 1.2 shares.
TO3 has expired on 1 December 2008. 2,866 shares have been excercised to subscribe for the same number of shares, raising the company SEK 5,732.

BALANCE SHEET

SEK m	31 Dec 2008	31 Dec 2007
Tangible fixed assets	0.4	0.5
Financial fixed assets	0.1	-
Current receivables	3.3	2.1
Cash & bank balances[1)]	3.3	5.3
Total assets	**7.1**	**7.9**
Shareholder's equity (see note below)	-1.1	-1.6
Long-term liabilities	1.9	3.0
Current liabilities	6.3	6.5
Total liabilities and shareholder's equity	**7.1**	**7.9**

1) of which SEK 0.2 m is blocked funds for rent as of 31 December 2008. As of 31 December 2007 SEK 0.3 m was blocked funds for rent and VPC (the Swedish Central Securities Depository & Clearing Organization.

STATEMENT OF CHANGES TO SHAREHOLDERS' EQUITY

SEK m	31 Dec 2008	31 Dec 2007
Shareholder's equity, opening balance	-1.6	31.1
New issue, 12,588 shares[2)]	-	0.2
Rights issue, 3,241,891 shares[2)]	14.9[1)]	-0.3
Rights issue, 1,718,246 shares[3)]	2.8	-
Private placement, 4,000,000 shares	5.0	-
Rights issue, 6,161,322 shares[4)]	2.7	-
New issue, 2,866 shares[4)]	0.0	-
Options	0.1	0.0
Net profit/loss	-24.9	-32.7
Shareholders' equity, closing balance	-1.1	-1.6

1) Includes issue costs of SEK 1.3 m
2) Conversion has been affected for the reverse stock split 1:10 carried out in June 2008.
3) Includes issue cost of SEK 0.7 m.
4) Paid-up, registered at the Swedish Companis Registrations Office on 15 January 2009, includes issue cost of SEK 0.4 m.

SHAREHOLDERS' EQUITY PER SHARE

SEK	31 Dec 2008	31 Dec 2007
Shareholders' equity per share	-0.06	-0.28

Shareholders' equity per share: shareholders´ equity divided by the number of outstanding shares at the end of the period.
Conversion has been affected for the bonus issue element of consummated rights issue.
Conversion has been affected for the reverse stock split 1:10 carried out in June 2008.

CASH FLOW STATEMENTS

SEK m	12 mth. Jan-Dec 2008	12 mth. Jan-Dec 2007
Cash flow from operating activities		
Net profit/loss	-24.9	-32.7
Depreciation	0.2	0.2
Change in long-term liabilities[1)]	-1.1	-1.3
Cash flow from operating activities before change in working capital	**-25.8**	**-33.8**
Cash flow from change in working capital		
Decrease/increase(-) in receivables	-1.2	-0.4
Decrease(-)/increase in current liabilities	-0.2	-0.4
Net cash flow used in operating activities	**-27.2**	**-34.6**
Cash flow from investment activities		
Acquisition of subsidiary/associated company	-0.1	-
Acquisition of tangible fixed assets	-0.1	-0.2
Net cash flow used in investment activities	**-0.2**	**-0.2**
Cash flow from financing activities		
New issue/capital contribution	25.4	-0.1
Cash flow from financing activities	**25.4**	**-0.1**
Cash flow for the period	-2.0	-34.9
Liquid assets, at start of period	5.3	40.2
Liquid assets, at end of period	**3.3**	**5.3**

1) A commitment over five years that Tripep undertook coincident with the acquisition of the ChronSeal wound healing project

KEY FIGURES

	3 mth. Oct-Dec 2008	3 mth. Oct-Dec 2007	12 mth. Jan-Dec 2008	12 mth. Jan-Dec 2007
Return on capital employed, %	neg	neg	neg	neg
Return on equity, %	neg	neg	neg	neg
Equity/assets ratio, %	neg	neg	neg	neg
Debt/equity ratio	neg	neg	neg	neg
Liquid assets, SEK m	3.3	5.3	3.3	5.3
Share risk-bearing capital, %	neg	neg	neg	neg
Cash flow for the period, SEK m	-0.7	-10.8	-2.0	-34.9
Investment in tangible fixed assets, SEK m	0.0	0.0	0.1	0.2
Internal research and development (written off), SEK m	0.1	0.4	0.9	1.1
External research and development (written off), SEK m	2.4	7.6	16.2	20.2
Salaries, benefits and social sequrity costs, SEK m	2.0	2.0	8.3	8.0
Average No. of employees	5	5	5	6